Traws Pharma, Inc. (TRAW) Institutional Ownership

Ownership Summary

A total of 19 institutions have reported a stake in Traws Pharma, Inc. (NASDAQ:TRAW) as of December 2025, according to recent 13F filings with the SEC.

• The percentage of Traws Pharma owned by institutions changed from 134.9% in September 2025 to 280.5% in December 2025, marking a slight up trend.
• The company experienced a 144.21% quarterly change in institutional shares held, alongside a decrease of 5.00% in total owners annually.
• Of these 19 institutional investors, 12 increased their holdings in Traws Pharma, while 2 of them reduced positions, and 5 investors maintained their exposure.
• The aggregate institutional position in Traws Pharma now stands at 2.69Mn shares as of December 2025, after investors increased their holdings (up by 1.59Mn shares quarter on quarter which is up 1.52Mn shares year over year).
• ADAGE CAPITAL PARTNERS GP, L.L.C.'s holding of 730.00K shares as of December 31, 2025 makes it the primary institutional investor in Traws Pharma, owning 76.09% of the stock.
• Among the most significant buyers of Traws Pharma during December 2025 were Squadron Capital Management LLC (713.54K), ADAGE CAPITAL PARTNERS GP, L.L.C. (400.00K), BOOTHBAY FUND MANAGEMENT, LLC (194.54K), ADAR1 Capital Management, LLC (154.43K), XTX Topco Ltd (42.21K).
• Leading sellers of Traws Pharma stock in December 2025 included CITIGROUP INC (3.53K), TWO SIGMA INVESTMENTS, LP (2.77K).
• The top 10 institutional holders of Traws Pharma for the quarter ending December 2025 included ADAGE CAPITAL PARTNERS GP, L.L.C. (730.00K), Squadron Capital Management LLC (713.54K), ORBIMED ADVISORS LLC (605.53K), BOOTHBAY FUND MANAGEMENT, LLC (194.54K), ADAR1 Capital Management, LLC (154.43K), VANGUARD GROUP INC (87.26K), GEODE CAPITAL MANAGEMENT, LLC (61.65K), XTX Topco Ltd (42.21K), STATE STREET CORP (25.80K), CITADEL ADVISORS LLC (24.82K).